Pfizer (PFE) stock is in focus as the FDA grants full approval for its colorectal cancer drug Braftovi, developed with Ono Pharmaceutical (OPHLF). Read more here.
Pfizer (PFE) stock is in focus as colorectal cancer therapy Braftovi as part of a combination regimen succeeds in a ...
GlobalData on MSN
Second Pfizer Braftovi regimen shows benefit in mCRC
This recent readout follows successful data from another combination including Braftovi in mCRC.
The experiences of Svedka, Alaska Airlines and Avocados From Mexico offer marketers a valuable reality check on the progress of AI-powered creative tools.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results